By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Biotechnology. According to news reporting out of Seoul, South Korea, by NewsRx editors, research stated, "Nanohybrid liposomes coated with amphiphilic hyaluronic acid-ceramide (HACE) was fabricated for targeted delivery of anticancer drug and in vivo cancer imaging. Nanohybrid liposomes including doxorubicin (DOX) and Magnevist, a contrast agent for magnetic resonance (MR) imaging, with 120-130 nm mean diameter and a narrow size distribution were developed."
Our news journalists obtained a quote from the research from the Korea Institute of Science and Technology, "DOX release from the developed formulation was improved at acidic pH (pH 5.5 and 6.8) versus physiological pH (pH 7.4). Cytotoxicity induced by the blank plain liposome was reduced by coating the outer surface of the nanohybrid liposome with HACE. Cellular uptake of DOX from the nanohybrid liposome was enhanced by HA and CD44 receptor interaction, versus the plain liposome. In vivo contrast-enhancing effects revealed that the nanohybrid liposome can be used as a tumor targeting MR imaging probe for cancer diagnosis. In a pharmacokinetic study in rats, in vivo clearance of DOX was decreased in the order DOX solution, plain liposome (F2), and nanohybrid liposome (F3), indicating prolonged circulation of the drug in the blood stream and improved therapeutic efficacy of the nanohybrid liposome (F3)."
According to the news editors, the research concluded: "Based on these findings, the nanohybrid liposomal system may be a useful candidate for real-time cancer diagnosis and therapy."
For more information on this research see: Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. Journal of Controlled Release, 2014;174():98-108. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
Our news journalists report that additional information may be obtained by contacting J.H. Park, Korea Inst Sci & Technol, Center Theragnosis, Biomed Res Inst, Seoul 136791, South Korea. Additional authors for this research include H.J. Cho, H.Y. Yoon, I.S. Yoon, S.H. Ko, J.S. Shim, J.H. Cho, J.H. Park, K. Kim, I.C. Kwon and D.D. Kim (see also Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Seoul, Cancer, Therapy, Oncology, Liposomes, South Korea, Drug Delivery Systems
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC